.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
US Army
McKinsey
Colorcon
Baxter
US Department of Justice
Accenture
Mallinckrodt
Harvard Business School
Covington

Generated: November 19, 2017

DrugPatentWatch Database Preview

XURIDEN Drug Profile

« Back to Dashboard

What is the patent landscape for Xuriden, and when can generic versions of Xuriden launch?

Xuriden is a drug marketed by Wellstat Therap and is included in one NDA. There is one patent protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries and two supplementary protection certificates in two countries.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.

Pharmacology for XURIDEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wellstat Therap
XURIDEN
uridine triacetate
GRANULE;ORAL208169-001Sep 4, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Wellstat Therap
XURIDEN
uridine triacetate
GRANULE;ORAL208169-001Sep 4, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Wellstat Therap
XURIDEN
uridine triacetate
GRANULE;ORAL208169-001Sep 4, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: XURIDEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,968,914 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides► Subscribe
7,166,581Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides► Subscribe
7,173,017Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis► Subscribe
6,344,447 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides► Subscribe
5,246,708 Methods for promoting wound healing with deoxyribonucleosides► Subscribe
7,105,498Acylated uridine and cytidine and uses thereof► Subscribe
5,691,320 Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis► Subscribe
6,306,834 Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
6,054,441 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis► Subscribe
7,169,765Acyl deoxyribonucleoside derivatives and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XURIDEN

Country Document Number Estimated Expiration
Russian Federation2203669► Subscribe
China1089239► Subscribe
Australia663309► Subscribe
Hong Kong1072897► Subscribe
Japan3885006► Subscribe
Japan3474073► Subscribe
Denmark1491201► Subscribe
European Patent Office0712629► Subscribe
JapanH101436► Subscribe
Israel100874► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: XURIDEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00036Denmark► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427
0889Netherlands► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACIL OF EEN ZOUT VAN TIPIRACIL, ZOALS TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Johnson and Johnson
Deloitte
Cantor Fitzgerald
Queensland Health
Farmers Insurance
Teva
Merck
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot